Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on improving vision through innovative therapies, has announced the granting of inducement awards to four newly hired employees. These awards, made under Ocular's 2019 Inducement Stock Incentive Plan, include:
1. Non-statutory stock options to purchase up to 132,400 shares of Ocular's common stock, with a ten-year term and a four-year vesting schedule.
2. Restricted stock unit awards representing the right to receive 44,133 shares of Ocular's common stock, with a three-year vesting schedule.
The grants, effective August 5, 2024, are designed to incentivize new employees and comply with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL), un'azienda biofarmaceutica focalizzata sul miglioramento della visione attraverso terapie innovative, ha annunciato l'assegnazione di premi di induzione a quattro nuovi dipendenti. Questi premi, concessi nell'ambito del Piano di Incentivazione Azionaria 2019 di Ocular, includono:
1. Opzioni su azioni non statutarie per l'acquisto di fino a 132.400 azioni delle azioni ordinarie di Ocular, con una durata di dieci anni e un programma di maturazione di quattro anni.
2. Premi in unità di azioni vincolate che rappresentano il diritto di ricevere 44.133 azioni delle azioni ordinarie di Ocular, con un programma di maturazione di tre anni.
Le concessioni, con effetto dal 5 agosto 2024, sono progettate per incentivare i nuovi dipendenti e per conformarsi alla Regola di Quotazione Nasdaq 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL), una empresa biofarmacéutica centrada en mejorar la visión a través de terapias innovadoras, ha anunciado la concesión de premios de inducción a cuatro nuevos empleados. Estos premios, otorgados bajo el Plan de Incentivos de Acciones de Inducción de 2019 de Ocular, incluyen:
1. Opciones de acciones no estatutarias para comprar hasta 132,400 acciones de las acciones ordinarias de Ocular, con un plazo de diez años y un calendario de adquisición de cuatro años.
2. Premios de unidades de acciones restringidas que representan el derecho a recibir 44,133 acciones de las acciones ordinarias de Ocular, con un calendario de adquisición de tres años.
Las concesiones, efectivas a partir del 5 de agosto de 2024, están diseñadas para incentivar a los nuevos empleados y cumplir con la Norma de Cotización de Nasdaq 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL)는 혁신적인 치료를 통해 시력을 개선하는 데 주력하는 바이오 제약 회사로, 네 명의 새로운 직원에게 유인 상을 수여한다고 발표했습니다. 이 상은 Ocular의 2019 유인 주식 인센티브 계획에 따라 제공되며, 포함된 내용은 다음과 같습니다:
1. Ocular의 보통주 132,400주를 구매할 수 있는 비상법적 주식 옵션으로, 10년의 기간과 4년의 분할 일정이 있습니다.
2. Ocular의 보통주 44,133주를 받을 권리를 나타내는 제한된 주식 단위 상으로, 3년의 분할 일정이 있습니다.
이 상은 2024년 8월 5일부터 유효하며, 신규 직원에게 인센티브를 제공하고 Nasdaq 상장 규칙 5635(c)(4)에 부합하도록 설계되었습니다.
Ocular Therapeutix (NASDAQ: OCUL), une entreprise biopharmaceutique axée sur l'amélioration de la vision grâce à des thérapies innovantes, a annoncé l'attribution de primes d'incitation à quatre nouveaux employés. Ces primes, accordées dans le cadre du Plan d'Incitation à l'Action 2019 d'Ocular, comprennent :
1. Options d'achat d'actions non statutaires permettant d'acheter jusqu'à 132,400 actions des actions ordinaires d'Ocular, avec une durée de dix ans et un calendrier d'acquisition de quatre ans.
2. Attributions d'unités d'actions restreintes représentant le droit de recevoir 44,133 actions des actions ordinaires d'Ocular, avec un calendrier d'acquisition de trois ans.
Les attributions, effectives à partir du 5 août 2024, sont conçues pour inciter les nouveaux employés et se conformer à la règle de cotation Nasdaq 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL), ein biopharmazeutisches Unternehmen, das sich auf die Verbesserung des Sehens durch innovative Therapien konzentriert, hat die Vergabe von Anreizprämien an vier neu eingestellte Mitarbeiter bekannt gegeben. Diese Prämien, die im Rahmen des Anreiz-Aktienplans 2019 von Ocular gewährt werden, umfassen:
1. Nicht statutarische Aktienoptionen zum Kauf von bis zu 132.400 Aktien der Stammaktien von Ocular, mit einer Laufzeit von zehn Jahren und einem vierjährigen Vesting-Plan.
2. Auszeichnungen von eingeschränkten Aktieneinheiten, die das Recht repräsentieren, 44.133 Aktien der Stammaktien von Ocular zu erhalten, mit einem dreijährigen Vesting-Plan.
Die Gewährungen, die ab dem 5. August 2024 wirksam sind, sollen neue Mitarbeiter anreizen und die Nasdaq-Listing-Regel 5635(c)(4) einhalten.
- Attracting new talent with stock incentives
- Aligning employee interests with company performance through equity awards
- Potential dilution of existing shareholders' equity
BEDFORD, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to four newly hired employees. The awards were made as inducements material to each individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards to the four newly hired employees were granted effective as of August 5, 2024 and consist of (i) non-statutory stock options to purchase up to an aggregate of 132,400 shares of Ocular’s common stock at a per share exercise price equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant and (ii) restricted stock unit awards representing the right to receive an aggregate of 44,133 shares of Ocular’s common stock. Each stock option has a ten-year term and is scheduled to vest over four years, with
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
What type of inducement awards did Ocular Therapeutix (OCUL) grant to new employees?
When were the inducement awards granted by Ocular Therapeutix (OCUL)?
How many new employees received inducement awards from Ocular Therapeutix (OCUL)?
What is the vesting schedule for the stock options granted by Ocular Therapeutix (OCUL)?
